Literature DB >> 21509650

Efficacy of adalimumab for a refractory case of relapsing polychondritis with reduction of pro-inflammatory cytokines.

Hideki Nakamura1, Takahisa Suzuki, Kentaro Nagaoka, Satoshi Yamasaki, Mami Tamai, Tomayoshi Hayashi, Atsushi Kawakami.   

Abstract

A 68-year-old man with a fever of unknown origin was admitted to our hospital. Bilateral auricularis and nasal root inflammation, with auricular perichondritis positive for anti-type II collagen (CII) antibody, led to a diagnosis of relapsing polychondritis (RP). Because the patient was refractory for high-dose glucocorticoid therapy, adalimumab was used. After the initiation of 40 mg of adalimumab, a rapid improvement of clinical manifestations, with a reduction in tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), together with a titer of anti-CII antibody was observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509650     DOI: 10.1007/s10165-011-0453-4

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  2 in total

1.  Relapsing polychondritis in a patient with ankylosing spondylitis using etanercept.

Authors:  Valderilio Feijó Azevedo; Natalia Bassalobre Galli; Alais Daiane Fadini Kleinfelder; Julia Farabolini D'Ippolito; Andressa Gulin Tolentino; Eduardo Paiva
Journal:  Case Rep Rheumatol       Date:  2014-09-09

2.  Assessment of TNF-α inhibitors in airway involvement of relapsing polychondritis: A systematic review.

Authors:  Josette Biya; Sandra Dury; Jeanne-Marie Perotin; Claire Launois; Maxime Dewolf; Gaëtan Deslée; François Lebargy
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.